menu
    • menu
    [{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"||RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Inapplicable"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Altesa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ALT-2023","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Innovation Ventures at Emory \/ Drug Innovation Ventures at Emory","highestDevelopmentStatusID":"5","companyTruncated":"Drug Innovation Ventures at Emory \/ Drug Innovation Ventures at Emory"}]

    Find Clinical Drug Pipeline Developments & Deals by Drug Innovation Ventures at Emory

    Menu

    Drug Innovation Ventures at Emory

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-2023,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Altesa Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Glob...

                            Details : The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 02, 2022

                            Lead Product(s) : ALT-2023,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Altesa Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Ridgeback Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Emory's DRIVE, Ridgeback partnering for drug vs coronavirus

                            Details : Ridgeback has exclusively licensed DRIVE's EIDD-2801 and will be responsible for advancing it through clinical development and ensuring that EIDD-2801 is available during current pandemic.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 23, 2020

                            Lead Product(s) : Molnupiravir,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Ridgeback Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Drug Innovation Ventures at Emory

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nonprofit drug development company starts GoFundMe for emergency funds to treat coronavirus

                            Details : DRIVE is developing the compound, designated EIDD-2801, which has shown efficacy against other coronaviruses such as SARS-CoV and MERS-CoV.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 27, 2020

                            Lead Product(s) : Molnupiravir,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth